GlassScriptPhysician profile
Frederick William Jung
NPI 1427443134
$1,416.57
in general payments reported to CMS, 2019-2025
15 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $523 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360 · Education: $56.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.28 |
| Education | $56.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $656.61 | 2023-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.00 | 2023-2025 | Ofev |
| Glaxosmithkline, LLC. | $157.45 | 2024-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $71.56 | 2024-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $58.82 | 2025 | Uptravi, Opsynvi |
| Chiesi USA, INC. | $56.29 | 2025 | |
| Eurofins Viracor, LLC | $46.76 | 2024 | |
| Philips North America LLC | $40.56 | 2024 | (Ak6) Vest Therapy |
| Inspire Medical Systems, INC. | $35.82 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $31.96 | 2023-2024 | Fasenra |
| Merck Sharp & Dohme LLC | $24.37 | 2024 | Zerbaxa, Recarbrio |
| Grifols USA, LLC | $23.19 | 2024 | Prolastin-C Liquid |
| Fisher & Paykel Healthcare INC | $22.60 | 2023 | Fisher & Paykel Healthcare |
| Csl Behring | $19.58 | 2023 | Kcentra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.